Iranian Red Crescent Medical Journal

Published by: Kowsar

Acid Folic Supplementation in Major Depressive Disorder Treatment: A Double-Blind Randomized Clinical Trial

Zahra Sepehrmanesh 1 , Abdollah Omidi 2 and Narges Gholampoor 1 , *
Authors Information
1 Department of Psychiatry, Kashan University of Medical Sciences, Kashan, IR Iran
2 Department of Psychology, Kashan University of Medical Sciences, Kashan, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: February 01, 2017, 19 (2); e33243
  • Published Online: August 4, 2016
  • Article Type: Research Article
  • Received: September 25, 2015
  • Revised: June 19, 2016
  • Accepted: July 17, 2016
  • DOI: 10.5812/ircmj.33243

To Cite: Sepehrmanesh Z, Omidi A, Gholampoor N. Acid Folic Supplementation in Major Depressive Disorder Treatment: A Double-Blind Randomized Clinical Trial, Iran Red Crescent Med J. 2017 ; 19(2):e33243. doi: 10.5812/ircmj.33243.

Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Francesca MM, Efisia LM, Alessandra GM, Marianna A, Giovanni CM. Misdiagnosed hypomanic symptoms in patients with treatment-resistant major depressive disorder in Italy: results from the improve study. Clin Pract Epidemiol Ment Health. 2014; 10: 42-7[DOI][PubMed]
  • 2. Komaram RB, Nukala S, Palla J, Nambaru LR, Kasturi SM. A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder. J Clin Diagn Res. 2015; 9(6)-8[DOI][PubMed]
  • 3. Eisendrath SJ, Gillung EP, Delucchi KL, Chartier M, Mathalon DH, Sullivan JC, et al. Mindfulness-based cognitive therapy (MBCT) versus the health-enhancement program (HEP) for adults with treatment-resistant depression: a randomized control trial study protocol. BMC Complement Altern Med. 2014; 14: 95[DOI][PubMed]
  • 4. Valladares A, Dilla T, Sacristan JA. [Depression: a social mortgage. Latest advances in knowledge of the cost of the disease]. Actas Esp Psiquiatr. 2009; 37(1): 49-53[PubMed]
  • 5. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013; 43(3): 471-81[DOI][PubMed]
  • 6. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015; 76(2): 155-62[DOI][PubMed]
  • 7. Smagula SF, Butters MA, Anderson SJ, Lenze EJ, Dew MA, Mulsant BH, et al. Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults. JAMA Psychiatry. 2015; 72(10): 1021-8[DOI][PubMed]
  • 8. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013; 14(5): 334-85[DOI][PubMed]
  • 9. Yaremco E, Inglis A, Innis SM, Hippman C, Carrion P, Lamers Y, et al. Red blood cell folate levels in pregnant women with a history of mood disorders: a case series. Birth Defects Res A Clin Mol Teratol. 2013; 97(6): 416-20[DOI][PubMed]
  • 10. Issac TG, Soundarya S, Christopher R, Chandra SR. Vitamin B12 deficiency: an important reversible co-morbidity in neuropsychiatric manifestations. Indian J Psychol Med. 2015; 37(1): 26-9[DOI][PubMed]
  • 11. Lang UE, Beglinger C, Schweinfurth N, Walter M, Borgwardt S. Nutritional aspects of depression. Cell Physiol Biochem. 2015; 37(3): 1029-43[DOI][PubMed]
  • 12. Assies J, Mocking RJ, Lok A, Koeter MW, Bockting CL, Visser I, et al. Erythrocyte fatty acid profiles and plasma homocysteine, folate and vitamin B6 and B12 in recurrent depression: Implications for co-morbidity with cardiovascular disease. Psychiatry Res. 2015; 229(3): 992-8[DOI][PubMed]
  • 13. Pourghassem Gargari B, Saboktakin M, Mahboob S, Pourafkari N. Nutritional status in patients with major depressive disorders: a pilot study in tabriz, iran. Health Promot Perspect. 2012; 2(2): 145-52[DOI][PubMed]
  • 14. Su KP, Wang SM, Pae CU. Omega-3 polyunsaturated fatty acids for major depressive disorder. Expert Opin Investig Drugs. 2013; 22(12): 1519-34[DOI][PubMed]
  • 15. Hintikka J, Tolmunen T, Tanskanen A, Viinamaki H. High vitamin B12 level and good treatment outcome may be associated in major depressive disorder. BMC Psychiatry. 2003; 3: 17[DOI][PubMed]
  • 16. Nowak G. Zinc, future mono/adjunctive therapy for depression: Mechanisms of antidepressant action. Pharmacol Rep. 2015; 67(3): 659-62[DOI][PubMed]
  • 17. Venkatasubramanian R, Kumar CN, Pandey RS. A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes. J Affect Disord. 2013; 150(2): 644-8[DOI][PubMed]
  • 18. Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badiale M, et al. Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano). 1993; 5(1): 63-71[PubMed]
  • 19. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000; 60(2): 121-30[PubMed]
  • 20. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002; 14(1): 33-8[PubMed]
  • 21. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol. 2004; 18(2): 251-6[DOI][PubMed]
  • 22. Lerner V, Kanevsky M, Dwolatzky T, Rouach T, Kamin R, Miodownik C. Vitamin B12 and folate serum levels in newly admitted psychiatric patients. Clin Nutr. 2006; 25(1): 60-7[DOI][PubMed]
  • 23. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012; 169(12): 1267-74[DOI][PubMed]
  • 24. Christensen H, Aiken A, Batterham PJ, Walker J, Mackinnon AJ, Fenech M, et al. No clear potentiation of antidepressant medication effects by folic acid+vitamin B12 in a large community sample. J Affect Disord. 2011; 130(1-2): 37-45[DOI][PubMed]
  • 25. Nahas R, Sheikh O. Complementary and alternative medicine for the treatment of major depressive disorder. Can Fam Physician. 2011; 57(6): 659-63[PubMed]
  • 26. Sanchez-Villegas A, Henriquez P, Bes-Rastrollo M, Doreste J. Mediterranean diet and depression. Public Health Nutr. 2006; 9(8A): 1104-9[DOI][PubMed]
  • 27. Astorg P, Couthouis A, de Courcy GP, Bertrais S, Arnault N, Meneton P, et al. Association of folate intake with the occurrence of depressive episodes in middle-aged French men and women. Br J Nutr. 2008; 100(1): 183-7[DOI][PubMed]
  • 28. Murakami K, Mizoue T, Sasaki S, Ohta M, Sato M, Matsushita Y, et al. Dietary intake of folate, other B vitamins, and omega-3 polyunsaturated fatty acids in relation to depressive symptoms in Japanese adults. Nutrition. 2008; 24(2): 140-7[DOI][PubMed]
  • 29. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry. 2003; 60(6): 618-26[DOI][PubMed]
  • 30. Ramos MI, Allen LH, Haan MN, Green R, Miller JW. Plasma folate concentrations are associated with depressive symptoms in elderly Latina women despite folic acid fortification. Am J Clin Nutr. 2004; 80(4): 1024-8[PubMed]
  • 31. Bottiglieri T, Reynolds EH, Laundy M. Folate in CSF and age. J Neurol Neurosurg Psychiatry. 2000; 69(4): 562[PubMed]
  • 32. Wolters M, Strohle A, Hahn A. [Age-associated changes in the metabolism of vitamin B(12) and folic acid: prevalence, aetiopathogenesis and pathophysiological consequences]. Z Gerontol Geriatr. 2004; 37(2): 109-35[DOI][PubMed]
  • 33. Reynolds EH. Benefits and risks of folic acid to the nervous system. J Neurol Neurosurg Psychiatry. 2002; 72(5): 567-71[PubMed]
  • 34. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000; 69(2): 228-32[PubMed]
  • 35. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev. 2008; 13(3): 216-26[PubMed]
  • 36. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: focus on folate. Nutrition. 2000; 16(7-8): 544-6[PubMed]
  • 37. Alpert JE, Fava M. Nutrition and depression: the role of folate. Nutr Rev. 1997; 55(5): 145-9[PubMed]
  • 38. Tolmunen T, Voutilainen S, Hintikka J, Rissanen T, Tanskanen A, Viinamaki H, et al. Dietary folate and depressive symptoms are associated in middle-aged Finnish men. J Nutr. 2003; 133(10): 3233-6[PubMed]
  • 39. Morris MS, Fava M, Jacques PF, Selhub J, Rosenberg IH. Depression and folate status in the US Population. Psychother Psychosom. 2003; 72(2): 80-7[DOI][PubMed]
  • 40. Gariballa S, Forster S. Effects of dietary supplements on depressive symptoms in older patients: a randomised double-blind placebo-controlled trial. Clin Nutr. 2007; 26(5): 545-51[DOI][PubMed]
  • 41. Stahl SM. L-methylfolate: a vitamin for your monoamines. J Clin Psychiatry. 2008; 69(9): 1352-3[PubMed]
  • 42. Moustafa AA, Hewedi DH, Eissa AM, Frydecka D, Misiak B. Homocysteine levels in schizophrenia and affective disorders-focus on cognition. Front Behav Neurosci. 2014; 8: 343[DOI][PubMed]
  • 43. Ghanizadeh A, Singh AB, Berk M, Torabi-Nami M. Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies. Expert Opin Ther Targets. 2015; 19(7): 927-39[DOI][PubMed]
  • 44. Kontoangelos K, Papageorgiou CC, Raptis AE, Tsiotra P, Lambadiari V, Papadimitriou GN, et al. Homocysteine, cortisol, diabetes mellitus, and psychopathology. J Diabetes Res. 2015; 2015: 354923[DOI][PubMed]
  • 45. Liu T, Zhong S, Liao X, Chen J, He T, Lai S, et al. A Meta-Analysis of Oxidative Stress Markers in Depression. PLoS One. 2015; 10(10)[DOI][PubMed]
  • 46. Budni J, Zomkowski AD, Engel D, Santos DB, dos Santos AA, Moretti M, et al. Folic acid prevents depressive-like behavior and hippocampal antioxidant imbalance induced by restraint stress in mice. Exp Neurol. 2013; 240: 112-21[DOI][PubMed]
  • 47. Aghamohammadi V, Gargari BP, Aliasgharzadeh A. Effect of folic acid supplementation on homocysteine, serum total antioxidant capacity, and malondialdehyde in patients with type 2 diabetes mellitus. J Am Coll Nutr. 2011; 30(3): 210-5[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments